Dr. Rick Bright says he raised concerns about US preparedness for Covid-19 in January but was met with ‘indifference which then developed into hostility’
Bright said in the complaint he raised urgent concerns about shortages of critical supplies, including masks, to his superiors in the Trump administration but was met with skepticism and surprise.
While Bright said some officials shared his concerns — including top White House trade adviser Peter Navarro — he describes an overall lack of action at the top of the administration even as the virus was spreading outside of China.
Bright had led the Biomedical Advanced Research and Development Authority since 2016 when he was reassigned last month to a narrower position at the National Institutes of Health.
In his whistleblower complaint, Bright says he raised concerns about US preparedness for coronavirus starting in January but was met with “indifference which then developed into hostility” by leaders at the Department of Health and Human Services.
Later, he says he pushed back on HHS’s leadership when they sought to make “potentially harmful drugs” available for treating Covid-19, including hydroxychloroquine, which had been repeatedly touted by Trump as a potential cure despite a lack of robust testing.
“His efforts to prioritize science and safety over political expediency and to expose practices that posed a substantial risk to public health and safety, especially as it applied to chloroquine and hydroxychloroquine, rankled those in the Administration who wished to continue to push this false narrative,” the complaint reads.
HHS declined a CNN request to comment on the complaint.
Bright’s decision to go public with his concerns last month exposed months of turmoil inside one of the key divisions at HHS charged with responding to the coronavirus pandemic. His allegations raised serious questions about political bias creeping into the government’s response to the pandemic and the extent to which Trump’s preferences for a drug overshadowed its scientific merits.
After he initially aired his complaints, administration officials leveled a range of allegations against Bright, including accusing him of poorly managing his office, mistreating staff and failing to consult his superiors on consequential decisions. But Bright’s most recent performance review from May 2019, a copy of which was obtained by CNN, delivered rave reviews for Bright’s management of his office and included no criticisms.
His attorneys argue that Bright’s removal from his post amounts to a violation of the Whistleblower Protection Act, claiming that Bright “has engaged in numerous instances of protected activity.”
In the complaint, he says he is seeking reinstatement as BARDA’s director and asking for a full investigation.
He claims leaders at the agency were surprised by his concerns and responded slowly to the outbreak, alleging old disputes with HHS leadership — including Secretary Alex Azar and Robert Kadlec, the assistant secretary for preparedness and response — were exacerbated by clashes over the coronavirus and that he was eventually excluded from participating in meetings about the virus.
“Dr. Bright pressed for urgent access to funding, personnel and clinical specimens, including viruses, which he emphasized were all critically necessary to begin development of lifesaving medicines needed in the likely event that the virus spread outside of Southeast Asia,” the complaint reads. “Secretary Azar and Dr. Kadlec responded with surprise at Dr. Bright’s dire predictions and urgency.”
Later, Bright claims he was cut out of critical meetings for raising early alarm about the virus.
“It was obvious that Dr. Bright’s persistent demands for urgent action to respond to the pandemic had caused a ‘shit storm’ and a ‘commotion’ and were unwelcome in the office of the HHS Secretary,” the complaint reads. “As a result, HHS leadership excluded Dr. Bright and BARDA from these recurring meetings and from the critical discussions about addressing the COVID-19 pandemic.”
As the outbreak persisted, Bright says he came under pressure from political leadership at HHS to make hydroxychloroquine widely available after Trump repeatedly proclaimed its potential benefits during his daily White House briefings.
At one point Trump even said he would take the drug himself to protect against the disease, although researchers have said there’s no evidence of its protective effects.
In his complaint, Bright says his concerns about hydroxychloroquine reached a tipping point after drugmaker Bayer offered to donate 3 million pills to the national stockpile.
In an email, another BARDA doctor advised Bright against accepting Bayer’s chloroquine donation because “there are safety liabilities associated with the drug … accepting the donation could send a signal that we are not concerned about the risk … Accepting the donation could lead to widespread use that is not supported by any clinical data.”
Bright also raised safety concerns related to the factories abroad where some of the pills were produced that had not been inspected by the US Food and Drug Administration.
In his complaint, Bright does identify one official who he says appeared to recognize the gravity of the outbreak: Navarro, the President’s hawkish trade adviser.
“Mr. Navarro asked good questions and was prepared to take prompt action to address this impending health crisis,” the complaint reads. “Mr. Navarro clearly recognized that Dr. Bright was unable to get any traction with HHS and was, to Dr. Bright’s great relief, prepared to act.”
In a lengthy series of exhibits that was included with Bright’s whistleblower complaint, some of the memos are provided, including warnings on shortages of masks and syringes to administer an eventual vaccine.
“We may find ourselves in a situation where we have enough vaccine but no way to deliver all of it,” Navarro wrote to members of the White House coronavirus task force on February 14.
This story has been updated with additional reporting.
